IT should be notified now!

Association for Behavior Analysis International

The Association for Behavior Analysis International® (ABAI) is a nonprofit membership organization with the mission to contribute to the well-being of society by developing, enhancing, and supporting the growth and vitality of the science of behavior analysis through research, education, and practice.

Search
Donate to SABA Capital Campaign
Portal Access Behavior Analysis Training Directory Contact the Hotline View Frequently Asked Question
ABAI Facebook Page Follow us on Twitter LinkedIn LinkedIn
  • AUT: Autism

    BPN: Behavioral Pharmacology and Neuroscience

    CBM: Clinical/Family/Behavioral Medicine

    CSS: Community, Social, and Sustainability Issues

    DDA: Developmental Disabilities

    DEV: Behavioral Development

    EAB: Experimental Analysis of Behavior

    EDC: Education

    OBM: Organizational Behavior Management

    PCH: Philosophical, Conceptual, and Historical Issues

    PRA: Practice

    TBA: Teaching Behavior Analysis

    VRB: Verbal Behavior

    SCI: Science

    OTH: Other

44th Annual Convention; San Diego, CA; 2018

Event Details

Previous Page

 

Invited Paper Session #388
Behavioral Pharmacology of Prescription Drugs: Their Effects on Learning and Remembering
Monday, May 28, 2018
8:00 AM–8:50 AM
Marriott Marquis, San Diego Ballroom B
Area: SCI
Instruction Level: Intermediate
CE Instructor: Mark Galizio, Ph.D.
Chair: Jonathan W. Pinkston (Western New England University)
MARK GALIZIO (University of North Carolina Wilmington)
Dr. Mark Galizio earned his Ph.D. from the University of Wisconsin-Milwaukee and currently serves as professor of psychology at the University of North Carolina Wilmington, having previously served as department chair (2004–2011). Dr. Galizio’s highly productive research career includes more than 80 published articles and chapters, a textbook now in its seventh edition, an edited book, more than $1 million in grants, service as associate editor and editorial board member of multiple prominent behavior analytic journals, and extensive leadership service to the field (e.g., president of APA Division 25, NIH Study Section on Biobehavioral Regulation, Learning, and Ethology). His contributions have included empirical, conceptual, and methodological advances across an impressive range of specialties within the experimental analysis of behavior, including rule-governed behavior, aversive control, complex stimulus control, behavioral pharmacology, and learning and remembering. His work exemplifies the best of the benefits of translational research, taking a thoroughly behavior analytic approach to issues of broader interest in the behavioral, social, and biological sciences, for which he has been recognized as a Fellow in four different divisions of APA. Dr. Galizio’s teaching and mentorship are also noteworthy, and have resulted in numerous awards and recognitions.
Abstract: This talk will provide a brief overview of procedures used in the behavioral pharmacology of learning and remembering with a focus on prescription drugs used to treat clients with intellectual disabilities. The talk will also provide a more detailed analysis of research using novel procedures that vary the number of stimuli to remember as well as the retention interval. We will briefly review findings from the animal laboratory on drugs that impair learning and memory as well as the search for “cognitive enhancers.” Factors that have made it difficult to translate findings from the animal behavioral pharmacology laboratory to improvements in human learning and remembering will be discussed and we will consider the implications of these difficulties for the treatment of clients with intellectual disabilities.
Target Audience: Researchers and practitioners interested in the behavioral pharmacology of learning and remembering.
Learning Objectives: At the conclusion of the presentation, participants will be able to: (1) identify and describe procedures used to study drug effects on learning and remembering in non-human subjects; (2) evaluate the strengths and limitations of these procedures with respect to internal validity and translational significance; (3) describe potential issues raised by the basic research literature that are relevant to pharmacotherapy.
 

BACK TO THE TOP

 

Back to Top
Modifed by Eddie Soh
SABA DONATE ABAI HOTLINE